Full history for every metric is available with a Kvantra account
LAVA Therapeutics N.V. (LVTX)
Key financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 4 | 5 | 19 | 7 | 12 | 5 |
| Operating profit | $m | -30 | -30 | |||||
| Net profit | $m | -10 | -16 | -42 | -32 | -42 | -25 | -23 |
| EPS reported | $ | -0.94 | -0.86 | |||||
| Operating cashflow per share | $ | -0.73 | -1.13 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -0.73 | -1.13 | |||||
| Free cash flow | $m | -20 | -32 | |||||
| Net debt | $m | -72 | -50 | |||||
| Book value equity | $m | 28 | 13 | |||||
| Book value per share | $ | 1.03 | 0.47 | |||||
| Number of shares | m | 26.83 | 26.9 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.92 | 3.61 | |||||
| P/S LTM | x | 2.13 | 9.17 | |||||
| P/FCF LTM | x | -1.30 | -1.45 | |||||
| EV/EBITDA LTM | x | 0.18 | 0.18 | |||||
| EV/Sales LTM | x | -0.35 | -0.78 | |||||
| Earnings Yield LTM | % | -98.41% | -41.25% | |||||
| FCF Yield | % | -76.67% | -69.19% | |||||
| Quality | ||||||||
| ROE | % | -90.52% | -99.17% | |||||
| ROIC | % | -43.65% | -47.04% | |||||
| Operating margin | % | -247.81% | 0.00% | |||||
| Gross margin | % | 100.00% | 0.00% | |||||
| FCF/Sales | % | -163.30% | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +77.01% | -32.06% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -3.71 | - | |||||
| Net Debt/EBITDA | x | 1.27 | 2.65 | |||||
| EBIT/Net interest | x | -57.66 | -173.88 | |||||
| Net debt/market cap | % | -280.92% | -108.50% | |||||
| Net debt/Equity | x | -2.58 | -3.92 | |||||
| Gross debt/equity | x | 0.19 | 0.00 | |||||
Company overview
LAVA Therapeutics N.V. is an immuno-oncology firm, currently in the clinical development phase, dedicated to pioneering novel therapies for cancer. Utilizing its proprietary Gammabody platform, the company engineers innovative bispecific antibodies. These antibodies are specifically designed to engage and harness the potent and precise capabilities of gamma delta T cells, aiming to stimulate a robust anti-tumor immune response and ultimately enhance outcomes for individuals battling cancer. Key compounds in its clinical pipeline include LAVA-051, currently undergoing Phase 1/2a trials for various hematologic malignancies such as chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia. Another front-runner, LAVA-1207, is also in Phase 1/2a clinical studies, targeting metastatic castration-resistant prostate cancer. Furthermore, LAVA Therapeutics is advancing additional Gammabody candidates: LAVA-1223, an investigational treatment for specific solid tumors that targets the epidermal growth factor receptor (EGFR), and preclinical assets LAVA-1266 and LAVA-1278, intended for a range of blood cancers. The company has also forged a research collaboration and licensing partnership with Janssen Biotech, Inc. This alliance focuses on the potential discovery and development of multi-specific antibody therapies aimed at a particular target across diverse therapeutic applications. Established in 2016, LAVA Therapeutics N.V. operates from its headquarters in Utrecht, the Netherlands.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
LAVA Therapeutics N.V. (LVTX)
LAVA Therapeutics N.V. is an immuno-oncology firm, currently in the clinical development phase, dedicated to pioneering novel therapies for cancer. Utilizing its proprietary Gammabody platform, the company engineers innovative bispecific antibodies. These antibodies are specifically designed to engage and harness the potent and precise capabilities of gamma delta T cells, aiming to stimulate a robust anti-tumor immune response and ultimately enhance outcomes for individuals battling cancer. Key compounds in its clinical pipeline include LAVA-051, currently undergoing Phase 1/2a trials for various hematologic malignancies such as chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia. Another front-runner, LAVA-1207, is also in Phase 1/2a clinical studies, targeting metastatic castration-resistant prostate cancer. Furthermore, LAVA Therapeutics is advancing additional Gammabody candidates: LAVA-1223, an investigational treatment for specific solid tumors that targets the epidermal growth factor receptor (EGFR), and preclinical assets LAVA-1266 and LAVA-1278, intended for a range of blood cancers. The company has also forged a research collaboration and licensing partnership with Janssen Biotech, Inc. This alliance focuses on the potential discovery and development of multi-specific antibody therapies aimed at a particular target across diverse therapeutic applications. Established in 2016, LAVA Therapeutics N.V. operates from its headquarters in Utrecht, the Netherlands.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free